Replies to post #35710 on OncoSec Medical Inc (ONCSQ)

[trading.jeff]

What difference does it make? Why should anyone care? INO is INO and ONCS is ONCS; apples and oranges, bud!! I can assure you I've done more than

very little DD

as have most of the other "regulars" here.

$ONCS

[Titan V]

Regarding ONCS's use of EP tech, they licensed it from INO in 2011 for a few $M if I'm not wrong and will not owe them any royalties or milestone payments from future revenue.

If the preliminary data from the Keytruda p2b melanoma combo trial this fall meets endpoints, ONCS may see a partnership offer from Merck for a registration trial.

An overlooked big pharma partnership ONCS already has is the preclinical one with Plexxikon. Plexxikon ceased to exist as an independent company after Daiichi Sankyo acquired it in 2011. Any trials stemming from the preclinical studies will have the financial backing of Daiichi Sankyo.

ONCS also has a preclinical agreement with Heat Biologics which is not a big pharma but with 4 critical data updates in lung (Opdivo combo) and bladder cancer (FDA Fast Track) this fall, it could shoot up to be a bigger company after which a phase 1 trial may eventually proceed with ONCS, giving ONCS access to two new cancer indications.

I think we are on the verge of things turning around for ONCS investors. You have found it at the right time if you can afford to take some risk.